Melanocortin receptor agonist
PT-141
Also known as Bremelanotide, Vyleesi
FDA-approved drugA peptide that acts on the brain’s melanocortin system, with one FDA approval.
Evidence
FDA-approved drug
Regulatory status
Prescription drug. FDA-approved for one specific indication.
Class
Melanocortin receptor agonist
What it is
Bremelanotide activates melanocortin receptors in the brain, which are involved in sexual desire. It works through the nervous system rather than blood flow.
What the research shows
- FDA-approved in 2019 (as Vyleesi) for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
- Nausea was the most commonly reported side effect in trials.
Read the published research on PubMed →
Researched for
PT-141 is a prescription medicine approved only for specific uses. A licensed provider decides whether it is appropriate for you.
Educational content, not medical advice. This page does not recommend or dose any substance.